BIOMIRA RESEARCH (BIOM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOMIRA RESEARCH (BIOM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: chirodoc who wrote (53)	2/17/2000 12:45:00 AM
From: chirodoc	Read Replies (2) of 72

ANALYSIS OF CEO'S PRESENTATION Biomera's CEO reported today, at the Biotechnology Industry Organization Conference, that the Phase II clinical trial, in "stage IIIb and stage IV non-small cell lung cancer" patients, has shown an outstanding response rate in this deadly disease. The "Phase II trial was a study utilizing a dosage of 1000 mg of BLP25, which has been shown to induce a very strong CTL immune response in six out of eight patients to date. To the Company's knowledge, this type of T-cell mediated cellular immune response has never been previously achieved in human carcinoma patients." Folks, this report is incredible considering the terminal stages of the disease. An immune response of 75% is UNHEARD of. When the official results are released, I expect this stock to explode upwards crossing $20 and then $30. However, I will not sell because, as we all know, the expected revenues are huge as lung cancer (mostly terminal) is sadly one of the deadliest diseases today

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next